You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
智飛生物(300122.SZ):26價肺炎球菌結合疫苗進入Ⅰ/Ⅱ期臨牀試驗
格隆匯 08-20 19:12

格隆匯8月20日丨智飛生物(300122.SZ)公佈,近日獲悉由全資子公司北京智飛綠竹生物製藥有限公司自主研發的26價肺炎球菌結合疫苗(簡稱“26價肺炎結合疫苗”)在河南省開展Ⅰ/Ⅱ期臨牀試驗。

肺炎鏈球菌有90多種血清型,但造成侵襲性感染的血清型相對集中在部分型別。智飛綠竹自主研發的26價肺炎結合疫苗為預防用生物製品,涵蓋了目前最常見的血清型,覆蓋更廣泛。26價肺炎結合疫苗擬使用對象為2月齡及以上人羣,用於預防肺炎鏈球菌相關血清型引起的侵襲性疾病。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account